论文部分内容阅读
目的:预混胰岛素血糖控制不佳者改用那格列奈联合中效人胰岛素(NPH)在2型糖尿病患者中的有效性及安全性。方法:选择应用预混人胰岛素3月及以上血糖控制不佳的2型糖尿病患者108例,分为2组,一组(42例)维持原方案的基础上调整预混胰岛素用量,另一组(66例)改用那格列奈联合中效人胰岛素治疗,随访3月及6月,比较治疗前后两组空腹血糖(FBG),餐后2 h血糖(2hPBS),糖化血红蛋白(HbA1c)及低血糖发生率,体重变化情况。结果:那格列奈联合中效人胰岛素与预混胰岛素治疗3月和1年时比较,FBG、2hPBS及HbA1c较治疗前均明显下降;同时低血糖发生率减少;体重及体重指数3月后无明显变化但1年后有所降低。结论:2型糖尿病患者应用那格列奈联合中效胰岛素能更好控制血糖;同时减少低血糖的发生率,不增加体重,兼顾了治疗的有效性及安全性,疗效优于预混胰岛素。
OBJECTIVE: To assess the efficacy and safety of pre-mixed insulin-poor glycemic control in patients with type 2 diabetes who switched to nateglinide with neutrophil insulin (NPH). Methods: One hundred and eighty patients with type 2 diabetes who had poor blood glucose control in March and above were enrolled in this study. They were divided into two groups, one group (42 cases). The dosage of premixed insulin was adjusted on the basis of the original plan. (N = 66) were treated with nateglinide combined with mid-effective insulin for 3 months and 6 months. The fasting blood glucose (FBG), postprandial blood glucose (2hPBS), HbA1c Hypoglycemia incidence, weight changes. Results: Compared with pretreatment, the levels of FBG, 2hPBS and HbA1c in nateglinide combined with midazolam and premixed insulin at 3 and 1 year were significantly decreased, while the incidence of hypoglycemia was decreased. The body mass and body mass index after 3 months No significant change but decrease after 1 year. Conclusion: The application of nateglinide combined with moderate-acting insulin in patients with type 2 diabetes can better control blood glucose; at the same time reduce the incidence of hypoglycemia, do not increase body weight, taking into account the effectiveness and safety of treatment, the effect is better than premixed insulin.